Oramed Pharmaceuticals, Inc. (ORMP) is down 1.54% Monday In Premarket Trading

Oramed Pharmaceuticals, Inc. (ORMP) is lower by Monday morning, with the stock decreasing -1.54% in pre-market trading to 3.19. ORMP's short-term technical score of 23 indicates that the stock has traded less bullishly over the last month than 77% of stocks on the market. In the Biotechnology industry, which ranks 129 out of 146 industries, ORMP ranks higher than 41% of stocks. Oramed Pharmaceuticals, Inc. has risen 2.21% over the past month, closing at $3.11 on July 24. During this period of time, the stock fell as low as $2.91 and as high as $3.62. ORMP has an average analyst recommendation of Sell. The company has an average price target of $3.65.

ORMP has an Overall Score of 32. Find out what this means to you and get the rest of the rankings on ORMP!

See Full ORMP Report

Oramed Pharmaceuticals, Inc. has a Long-Term Technical rank of 52. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 48% of the market scoring higher. In the Biotechnology industry which is number 129 by this metric, ORMP ranks better than 129% of stocks.

Important Dates for Investors in ORMP:

-Oramed Pharmaceuticals, Inc. is set to release earnings on 2023-11-08. Over the last 12 months, the company has reported EPS of $0.28. -We do not have a set dividend date for Oramed Pharmaceuticals, Inc. at this time. Click Here To Get The Full Report on Oramed Pharmaceuticals, Inc. (ORMP)